https://www.prnewswire.com/news-releases/natera-chosen-for-longitudinal-circulating-tumor-dna-study-in-breast-cancer-300547101.html
/PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Imperial College...
circulating tumor dnanaterachosenlongitudinalstudy
https://www.natera.com/resource-library/anora/?type=Patient
Resources related to Anora miscarriage genetic testing
anoranatera
https://www.natera.com/info/onctrials/
May 30, 2025 - Natera invites you to be part of the community that helps address colorectal cancer care. Click here to learn more!
naterasponsoredtrials
https://www.natera.com/info/smart/
Apr 8, 2025 - Panorama 22q11.2 deletion findings from the SMART study have now been published in the American Journal of Obstetrics & Gynecology. Learn more.
smartstudynatera
https://pen.org/the-pen-ten-an-interview-with-cleyvis-natera/
Sep 17, 2025 - In this PEN Ten interview, we spoke with Cleyvis Natera, author of Neruda on the Park (Ballantine Books 2022).
the pencleyvis naterateninterviewamerica
https://www.macrotrends.net/stocks/charts/NTRA/natera/financial-statements
Ten years of annual and quarterly financial statements and annual report data for Natera (NTRA). Income statements, balance sheets, cash flow statements and...
financial statementsnaterantra
https://stockhouse.com/companies/insiders?symbol=ntra
See what company insiders are buying and selling at Natera Inc (NDAQ:NTRA). Use this to inform yourself about what officers and directors may be thinking.
ndaqntrainsidertransactionsnatera
https://www.natera.com/resource-library/altera/?type=Patient
Resources related to Altera tumor genomic profiling testing.
alteraresourcesnatera
https://www.natera.com/oncology/signatera-advanced-cancer-detection/patients/
Oct 22, 2025 - Signatera™ is a sensitive ctDNA test for colorectal cancer that can identify relapse sooner than standard tools. Click here to learn more about it.
patientsnatera